Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

July 31, 2007

Conditions
Anemia, Sickle Cell
Interventions
DRUG

ICL670, deferoxamine

Trial Locations (34)

10021

Weill Medical College of Cornell University, New York

10467

Sickle Cell Center, Montefiore Hospital, The Bronx

11215

NY Methodist Hospital, Brooklyn

14642

U. Of Rochester Medical Center, Rochester

15213

Children's Hospital of Pittsburgh, Pittsburgh

17033

Penn State Milton S Hershey Medical Center, Hershey

19104

Children's Hospital of Philadelphia, Philadelphia

20059

Howard University Hospital, Washington D.C.

23507

Children's Hospital of the King's Daughter, Norfolk

27106

Wake Forest University School of Medicine, Winston-Salem

29150

Santee Hematology/Oncology, Sumter

29203

Liberty Hematology Oncology Center, Columbia

Palmetto Health Clinical Trials, Columbia

30335

Georgia Comprehensive Sickle cell Center, Grady Hospital, Atlanta

30912

Adult Sickle Cell Clinic, Medical College of Georgia, Augusta

33607

Tampa Children's Hospital at St Joseph's, Tampa

36604

U. of S. Alabama Medical Center, Mobile

43210

James Cancer Hospital, Columbus

45219

Barrett Center, University of Cincinnati, Cincinnati

45229

Children's Hospital Medical Center, Cincinnati

48201

Karmanos Cancer Institute, Detroit

60612

University of Illinois at Chicago, Chicago

60614

Children's Memorial Hospital, Chicago

70112

Tulane University Sickle Cell Center, New Orleans

70118

Children's Hospital, Department of Hematology/Oncology, New Orleans

76508

Scott and White Memorial Hospital & Clinics, Temple

77030

Baylor College of Medicine, Houston

Texas Children's Hospital/Baylor College of Medicine, Houston

80262

Colorado Sickle Cell Treatment and Research Center, Denver

90027

Children's Hospital Los Angeles, Los Angeles

92354

Loma Linda University Medical Center, Loma Linda

94609

Children's Hospital & Research Center, Oakland

02115

Children's Hospital Boston, Division of Hematology/Oncology, Boston

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00067080 - Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions | Biotech Hunter | Biotech Hunter